🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesCoronary artery calcium score changes on GLP-1 — my results so far Page 2

Coronary artery calcium score changes on GLP-1 — my results so far

carl_compliance Sat, Oct 4, 2025 at 8:59 PM 10 replies 1,250 viewsPage 2 of 2
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Oct 5, 2025 at 12:09 AM#6
Dr.GastroMayo said:
Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

5 8SkepticalSean, Dr.CardioMD, EndoResFellow and 2 others
Reply Quote Save Share Report
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Oct 5, 2025 at 1:23 AM#7
carl_compliance said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 52" → 36" ✅ Resolved
  2. Triglycerides: 230 → 115 ✅ Resolved
  3. HDL: 36 → 52 ✅ Resolved
  4. Blood pressure: 140/96 → 118/72 ✅ Resolved
  5. Fasting glucose: 125 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

6 9NicoleRaleigh, james_edin, FranDenver and 3 others
Reply Quote Save Share Report
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Oct 5, 2025 at 2:37 AM#8
RetaRick_CA said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.
RetaRick_CA said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

7 10BrianDallas92, labquiet_amy, emily_PDX and 4 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
Oct 5, 2025 at 3:51 AM#9

Following on from zoe_NC — and this may be the naive question:

What did you change at the same time, and can you separate the two now?

8 11TirzTom, TrialTracker_MD, JennaRN and 5 others
Reply Quote Save Share Report
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Oct 5, 2025 at 9:47 AM#10
NurseAsh_DET said:
RetaRick_CA said: ...cardiovascular risk is just another fad...

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off lisinopril entirely! My cardiologist is thrilled.

If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.

14 14dave_SLC, FDA_TrackerJim, ricardo_MIA and 11 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register